Expanded Access for ATB200/AT2221 for the Treatment of Pompe Disease

NCT03865836 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2025-09-15

No results posted yet for this study

Summary

This is an expanded access program (EAP) for eligible participants designed to provide access to ATB200/AT2221.

Conditions

  • Pompe Disease

Interventions

BIOLOGICAL

ATB200

DRUG

AT2221

Sponsors & Collaborators

  • Amicus Therapeutics

    lead INDUSTRY

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03865836 on ClinicalTrials.gov